Associations - POLE mutation

POLE mutation POLE mutation	Solid Tumor Solid Tumor	POLE mutation POLE mutation	Solid Tumor Solid Tumor	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	CP-675206 Sensitive: C2 – Inclusion Criteria	CP-675206 Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	POLE mutation POLE mutation	Gastric Cancer Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Solid Tumor Solid Tumor	POLE mutation POLE mutation	Solid Tumor Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria	avelumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria	avelumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Solid Tumor Solid Tumor	POLE mutation POLE mutation	Solid Tumor Solid Tumor	toripalimab Sensitive: C2 – Inclusion Criteria	toripalimab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Colorectal Cancer CRC	POLE mutation POLE mutation	Colorectal Cancer CRC	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Solid Tumor Solid Tumor	POLE mutation POLE mutation	Solid Tumor Solid Tumor	dostarlimab Sensitive: C2 – Inclusion Criteria	dostarlimab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Melanoma Melanoma	POLE mutation POLE mutation	Melanoma Melanoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Colorectal Cancer CRC	POLE mutation POLE mutation	Colorectal Cancer CRC	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Melanoma Melanoma	POLE mutation POLE mutation	Melanoma Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Colorectal Cancer CRC	POLE mutation POLE mutation	Colorectal Cancer CRC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Melanoma Melanoma	POLE mutation POLE mutation	Melanoma Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Colorectal Cancer CRC	POLE mutation POLE mutation	Colorectal Cancer CRC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Colorectal Cancer CRC	POLE mutation POLE mutation	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Gastroesophageal Cancer Gastroesophageal Cancer	POLE mutation POLE mutation	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	POLE mutation POLE mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C4 – Case Studies	nivolumab Sensitive: C4 – Case Studies